AxSpA and IBD Treatment: Expert Insights on NSAIDs and Biologics

Managing patients who suffer from both axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) presents a complex clinical challenge due to the conflicting requirements of the two conditions. Medical experts, as reported by Medscape, highlight a significant tension in treatment strategies, where the first-line therapy for one condition may exacerbate the symptoms of the other.

Axial spondyloarthritis is a chronic inflammatory disease that primarily affects the axial skeleton, including the spine, pelvis and sacroiliac joints. When this condition coexists with IBD—which includes Crohn’s disease and ulcerative colitis—physicians must navigate a narrow therapeutic window to control systemic inflammation without triggering a flare-up in the gastrointestinal tract.

The NSAID Dilemma

Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically the first line of defense for treating the pain and stiffness associated with axSpA. These medications are effective at reducing inflammation in the joints and spine, providing essential relief for patients who often experience debilitating back pain.

However, the use of NSAIDs is highly contentious in patients with coexisting IBD. Experts caution that these drugs can compromise the intestinal mucosal barrier and may trigger an exacerbation of IBD symptoms or lead to a full disease flare. This creates a clinical paradox where the primary medication used to manage spinal pain can potentially worsen the patient’s bowel inflammation.

Because of these risks, specialists often recommend a cautious approach to NSAIDs in this patient population. In some cases, short-term or low-dose usage may be permitted, but the goal is frequently to transition the patient to therapies that address both inflammatory pathways simultaneously.

Navigating Biologic Therapies

When NSAIDs are contraindicated or insufficient, biologics become the primary focus of treatment. The choice of biologic is critical because different classes of these medications have varying effects on the gut and the spine.

Tumor necrosis factor (TNF) inhibitors are widely regarded by experts as the preferred biologic for patients with both axSpA, and IBD. These agents are unique in their ability to provide therapeutic benefits for both the axial skeleton and the intestinal lining, making them a dual-purpose tool for managing co-morbid inflammatory conditions.

In contrast, Interleukin-17 (IL-17) inhibitors, while highly effective for the spinal inflammation associated with axSpA, are viewed with caution in the context of IBD. There is evidence and expert concern that IL-17 inhibitors may exacerbate IBD or promote the development of new bowel inflammation. These drugs are generally avoided or used with extreme caution in patients with a known history of inflammatory bowel disease.

Combination Strategies and Future Directions

The discussion among experts also extends to the use of drug combinations. While the use of multiple biologics is generally avoided due to an increased risk of serious infections and other safety concerns, the combination of a biologic with a conventional synthetic disease-modifying antirheumatic drug (DMARD) is a common strategy in IBD management to maintain remission and prevent the development of antibodies against the biologic.

The emergence of Janus kinase (JAK) inhibitors represents another area of exploration. These oral medications target different signaling pathways than TNF or IL-17 inhibitors and may offer an alternative for patients who do not respond to traditional biologics, though their long-term profile in dual-diagnosis patients continues to be monitored.

The Importance of Multidisciplinary Care

Given the risks associated with crossing treatment lines, experts emphasize the necessity of a coordinated, multidisciplinary approach to care. Effective management typically requires close collaboration between a rheumatologist, who manages the axSpA, and a gastroenterologist, who manages the IBD.

This collaborative model ensures that a medication prescribed to treat joint pain does not inadvertently cause a gastrointestinal crisis, and vice versa. Regular communication between specialists allows for the titration of dosages and the timely switching of therapies based on the activity levels of both diseases.

the goal for patients with coexisting axSpA and IBD is the achievement of low disease activity in both domains. By prioritizing therapies with dual efficacy and avoiding high-risk triggers like certain NSAIDs or IL-17 inhibitors, clinicians aim to improve the overall quality of life and long-term prognosis for these patients.